BYSI Stock Forecast: BeyondSpring, Inc. Price Predictions for 2026-2027
Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 11 of 100 as at 21 Nov 2026 — in the weakest quartile.
One number for the whole business
Consensus tells you what everyone already believes. The model scores BeyondSpring, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Issuance (47): The share count has been shrinking and the company is not leaning on new borrowing.
Growth (10): Sales and profits are flat, shrinking, or growing more slowly than they were.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
BYSI stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on BYSI, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 2 May 2023 | Baird | Maintains | Outperform | $4.00 → $1.25 |
| 2 Dec 2021 | B of A Securities | Downgrade | Underperform | — |
| 2 Dec 2021 | Jefferies | Downgrade | Hold | — |
| 1 Dec 2021 | HC Wainwright & Co. | Downgrade | Neutral | — |
| 20 Sept 2021 | HC Wainwright & Co. | Maintains | Buy | — |
| 9 Sept 2021 | Baird | Initiates | Outperform | — |
| 4 Aug 2021 | HC Wainwright & Co. | Upgrade | Buy | — |
| 5 Apr 2021 | HC Wainwright & Co. | Downgrade | Neutral | — |
| 11 Jan 2021 | B of A Securities | Initiates | Buy | — |
| 29 Dec 2020 | Evercore ISI Group | Initiates | Outperform | — |
| 15 June 2020 | HC Wainwright & Co. | Maintains | Buy | — |
| 30 Mar 2020 | HC Wainwright & Co. | Maintains | Buy | — |
| 7 Feb 2020 | Jefferies | Initiates | Buy | — |
| 10 Jan 2020 | Nomura | Initiates | Buy | — |
| 10 Jan 2020 | Nomura Instinet | Initiates | Buy | — |
| 3 Dec 2019 | William Blair | Initiates | Outperform | — |
| 22 June 2018 | Maxim Group | Maintains | Buy | — |
| 4 Apr 2017 | Rodman & Renshaw | Initiates | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
This page is one stock. Monday covers all of them.
BYSI appears in the Radar on the weeks it earns a place.
- Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
- The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and servers
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
BYSI vs the S&P 500
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 20 Nov 2026, BeyondSpring, Inc. returned −82.0% against +6.9% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
BYSI analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Financials
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- —
- Price / sales
- —
- Price / book
- —
- EV / EBITDA
- —
- Revenue growth (YoY)
- —
- Earnings growth (YoY)
- —
- Gross margin
- —
- Operating margin
- —
- Net margin
- —
- Return on equity
- —
- Return on assets
- −22.4%
- Dividend yield
- —
Higher than 18% of US stocks
Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.
Key statistics
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
BeyondSpring, Inc. has a market value of $18.1M and an enterprise value of $17.6M.
Revenue in the twelve months to 30 June 2026: $0.0.
Net income over the same four quarters: −$23.1M.
Free cash flow in the twelve months to 30 June 2026: −$16.7M.
BeyondSpring, Inc. employs 44 people.
Data provided by Twelve Data
BYSI and its peers
The nearest names by industry and size, scored by the same model — like for like.
Take a look at BYSI’s peer groups, ranked by the model: healthcare stocks · biotech stocks.
Look up any of the roughly 4,300 stocks we score.
The rank is the raw material. Whether the rules would actually own BeyondSpring, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Questions about BYSI
How does Ticker Nerd's model rank BYSI?
As at 21 Nov 2026, BeyondSpring, Inc. ranks 11 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Issuance (47 of 100).
What is the BYSI stock forecast for 2030?
No analyst covering BeyondSpring, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for BYSI are extrapolating price history, which says nothing about the business.
How has BYSI stock performed over the past year?
BeyondSpring, Inc. returned -82.0% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.
What does BeyondSpring, Inc. do?
BeyondSpring Inc. is a clinical-stage biopharmaceutical company focused on developing oncology therapies, with an emphasis on immuno-oncology and cancer-supportive care. The company’s core programs center on Plinabulin, a lead candidate being studied for use in non-small cell lung cancer and in the prevention of chemotherapy-induced neutropenia, a condition that can complicate cancer treatment.
About BeyondSpring, Inc.
BeyondSpring Inc. is a clinical-stage biopharmaceutical company focused on developing oncology therapies, with an emphasis on immuno-oncology and cancer-supportive care. The company’s core programs center on Plinabulin, a lead candidate being studied for use in non-small cell lung cancer and in the prevention of chemotherapy-induced neutropenia, a condition that can complicate cancer treatment. BeyondSpring also operates a TPD platform that supports the discovery and development of therapeutic agents and new chemical entities. Its work is directed at addressing unmet needs in cancer care through targeted drug development and clinical research. Headquartered in Florham Park, New Jersey, BeyondSpring Inc. plays a specialized role in the biotechnology market as a research-driven company advancing late-stage and early-stage therapeutic candidates.
CEO Dr. Lan Huang Ph.D. · 44 employees · United States · https://beyondspringpharma.com